Rejection No. 2 for Medexus' decades-old chemo drug; Trevi touts chronic cough data
Researchers have been studying the chemotherapy drug treosulfan in patients since at least the time US astronauts landed on the moon. Decades of research doesn’t necessarily equate to an easy approval path, however.
Medexus and its parent Medac have found out again that the FDA had rejected the chemotherapy, the company said Monday. The second rejection comes 13 months after the first. In Canada, patients can receive the drug, where it’s known as Trecondyv.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
